CTNF 18/019,031 CTNF 69417 Notice of Pre-AIA or AIA Status 07-03-aia AIA 15-10-aia The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Claim Rejections - 35 USC § 102 07-06 AIA 15-10-15 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. 07-07-aia AIA 07-07 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – 07-08-aia AIA (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 07-15 AIA Claim (s) 1, 2, 5, 8-12 and 14 are rejected under 35 U.S.C. 102( a)(1 ) as being clearly anticipated by Park (KR 10-2020-0017727) Park discloses an organic electronic element comprising a first electrode, a second electrode, and an organic material layer formed between the first electrode and the second electrode, wherein the organic material layer comprises a phosphorescent light-emitting layer, and the host of the phosphorescent light-emitting layer comprises a first compound, a second compound, and a third compound (see claim 1), and the third compound is represented by chemical formula 3-3 (: X7 = O, S; X8 = a single bond), and the second compound includes Compound 2-144 () (see claims 1, 13, and 14). Compound 3-109 of Park is the same as the compound of Chemical Formula 1 of claims 1, 2, 5, 8-10, and 14, wherein X = O; L1, L2 = direct bond; R1-R6 = hydrogen; Ar1 = heterocyclic group substituted with diphenyl group (triazinyl group); Ar2 = heterocyclic group substituted with a phenyl group (benzimidazole group). Compound 2-144 of Park is the same as the compound of Chemical Formula 6 of claims 12 and 14, wherein Z1-Z3 = N; Ar6, Ar7 = unsubstituted aryl group having 6 carbon atoms (phenyl group); and Ar8 = heteroaryl group having 16 carbon atoms substituted with a phenyl group (7H-benzo [C] carbazole group). With respect to claim 11, Park indicates that the organic material layer includes a hole injection layer, a hole transport layer, a light emitting layer, an electron transport layer, an electron injection layer, and the like (see paragraph [0033]) . Claim Rejections - 35 USC § 103 07-20-aia AIA The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 07-21-aia AIA Claim (s) 3, 4, 6, 7, 13 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over Park (KR 10-2020-0017727) as described above . Compound 3-109 in Park May be selected from the group consisting of X = O in Formula 3 of claim 3; L1, L2 = direct bond; R1-R6 = hydrogen; N-Het = a compound that is a heterocyclic group (triazinyl group) substituted with a diphenyl group; In Chemical Formula A -1 of claim 4, X1, X3, X5 = N; X2 = CR12, X4 = CR14; R12, R14 = an unsubstituted aryl group (phenyl group) having 6 carbon atoms; in Chemical Formula 1 of claim 6, X = O; L1, L2 = direct bond; R1-R6 = hydrogen; Ar1 = heterocyclic group substituted with diphenyl group (triazinyl group); and Compound 1 of claim 7. Chemical Formula 3 of claims 3 and 4 differs from Park in that-(L2) n-N (R8) (R9) is substituted, claim 6 differs from Park in that at least one of Ar 1 and Ar 2 is a substituted or unsubstituted amine group, and compound 1 of claim 7 is substituted with an amine group at position 1 of the dibenzofuranyl group. However, considering that in Chemical Formula 3-3 disclosed in Park, Y14 is C (Rc), Rc is La-N (Ra) (Rb), and Ra and Rb are selected from hydrogen, deuterium, an aryl group, a heterocyclic group, and the like (see claims 1 and 11), these different features could be derived by a person skilled in the art through a substituent change. In addition, the effects resulting from the difference could also be sufficiently predicted from Park. Compound 1-17 in claim 13 differs from Park in that a naphtho [1,2-b] benzofuranyl group is substituted, but the difference could be derived by a person skilled in the art by changing the type of heteroatom in a heterocyclic group and the binding position thereof. In view of the fact that the mixture of the first host, the second host, and the third host in a weight ratio of 5: 3: 2 is used as a host in Park (see paragraph [0568]), a person skilled in the art could derive an optimized numerical range through repeated experiments. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES D SELLS whose telephone number is (571)272-1237. The examiner can normally be reached M-Th 8:30-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Phillip Tucker can be reached at 571-272-1095. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JAMES D. SELLS Primary Examiner Art Unit 1745 /JAMES D SELLS/ Primary Examiner, Art Unit 1745 Application/Control Number: 18/019,031 Page 2 Art Unit: 1745 Application/Control Number: 18/019,031 Page 3 Art Unit: 1745 Application/Control Number: 18/019,031 Page 4 Art Unit: 1745 Application/Control Number: 18/019,031 Page 5 Art Unit: 1745